Duncan Williams Maintains Medicis Pharmaceutical Buy, $43 PT

Duncan Williams maintained its Medicis Pharmaceutical MRX Buy rating and $43 price target in a research report published today. In the report, Duncan Williams states, "(1) Medicis plans to initiate new marketing initiatives on Solodyn and Dysport in 3Q11 which are expected to drive additional growth; (2) We have more visibility into new Dysport formulations and indications in development which could facilitate longer-term growth; and (3) We believe that the Solodyn switch has exceeded switch expectations of 90% and the brand is poised to resume growth in 2H11." Shares of Medicis Pharmaceutical closed today at $37.82, up 3.19% from Monday's market close.